Introduction
============

Multiple primary cancers (MPC) often arise simultaneously or metachronously with esophageal squamous cell carcinoma (ESCC). Most MPC occur in the aerodigestive tract, including the head-and-neck region, lungs and esophagus, with an incidence from 7.7% to 20.7% [@B1]-[@B4]. According to Warren and Gates, when MPC develop within 6 months after the diagnosis of the index cancer, they are considered to be synchronous [@B5], and these accounts for about half of all MPC with esophageal cancers [@B2]-[@B4], [@B6].

Demonstrated by previous studies, MPC and esophageal non-multiple primary cancer (NPC) were of distinct characteristics, as a reflection of different gene background and environmental conditions [@B7]. The complexity of the tumor type, as well as different location and stage of MPC, has constrained a consensus on the optimal treatment. Regretfully, attempts on extensive surgery have shown limited R0 resection rates and variating clinical outcomes [@B8]-[@B10]. Though several reports have focused on the efficacy and toxicity of concurrent chemoradiotherapy (CRT) [@B11]-[@B13], a direct comparison between MPC and NPC patients, with balanced baseline characteristics and relatively homogenous treatment modalities, had not been available. Thus, we designed the retrospective study to determine the efficacy and toxicity of concurrent CRT in patients with synchronous MPC and ESCC, with comparison by NPC counterparts.

Materials and Methods
=====================

The study was reviewed and approved by the institutional review board of Sun Yat-sen University Cancer Center and conducted according to the principles expressed in the Declaration of Helsinki. Because the study was a retrospective and anonymous analysis of routine data, we requested and were granted a waiver of individual informed consent.

Patient characteristics
-----------------------

From Jan 2011 to May 2015, a total of 1193 consecutive patients with a pathological diagnosis of ESCC and who received radiotherapy at Sun Yat-sen University Cancer Center were retrospectively screened. Among this cohort, 53 patients were identified as having at least one synchronous MPC in the upper digestive tract and underwent concurrent CRT. The standards proposed by Warren and Gates were satisfied: (1) all tumors were histologically confirmed; (2) all lesions were anatomically discontinuous and surrounded by normal tissue; and (3) distant metastases were excluded [@B5]. Tumors were diagnosed synchronously within an interval not exceeding 6 months. Clinical staging was based on the American Joint Committee on Cancer 2002 Criteria and consisted of comprehensive evaluations that included barium swallow, endoscopic ultrasonography (EUS), computed tomography (CT) of the neck, chest and abdomen, as well as MRI of the head and neck area or whole-body PET/CT, if necessary. Metastatic lymph nodes were considered as regional nodes of the primary ESCC if located in its drainage area; otherwise, they were evaluated as positive nodes of MPC, or distant metastasis if they were outside the region of both neoplasms.

Another 53 patients with single pathological diagnosed ESCC, who were treated with concurrent chemoradiotherapy during the same period, were consecutively included. Essential parameters, including stage, age and sex were manually matched. These patients were considered as the control group.

Treatments
----------

All patients received external beam radiation and concurrent chemotherapy, with or without systemic neoadjuvant chemotherapy. Three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT) were adopted using a 6-8 MV photon beam and conventional fraction (1.8-2.4 Gy). At least 50 Gy was delivered to primary esophageal cancer. During radiotherapy, chemotherapy regimens were consisted either of a single agent of platinum or 5-fluorouracil (5-FU) or of a double-drug combination of taxane+platinum (TP) or platinum+5-fluorouracil (PF), given every week (platinum 25 mg/m^2^ or 5-FU 1.33 g/m^2^ civ 72 hours or taxane 25 mg/m^2^+platinum 25 mg/m^2^ or platinum 25 mg/m^2^ +5-fluorouracil 1.33 g/m^2^ civ 72 hours, d1, d8, d15, d22) or every three weeks (platinum 75 mg/m^2^ or 5-FU 4.0 g/m^2^ civ 120 hours or taxane 75 mg/m^2^+platinum 75 mg/m^2^ or platinum 75 mg/m^2^ +5-fluorouracil 4.0 g/m^2^ civ 120 hours, d1, d22).

Response evaluation and follow-up
---------------------------------

Comprehensive re-evaluation work-ups conducted 2 months after the completion of CRT were studied by an experienced radiation oncologist. Responses were assessed according to Response Evaluation Criteria in Solid Tumors version 1.1. Acute and late toxicities were collected retrospectively and presented on the basis of Radiation Therapy Oncology Group grading. Follow-up evaluation was performed every 3 months during the first 2 years after treatment, every 6 months in the third year and once a year thereafter, including the examinations mentioned above.

Study end points
----------------

The primary endpoint was overall survival (OS) and treatment toxicity. The secondary endpoints were progression-free survival (PFS), locoregional progression-free survival (LRPFS) and distant progression-free survival (DPFS). OS was defined as the time from initial diagnosis (for both primary and secondary cancers) to death from any cause. PFS was defined as the time from diagnosis to disease progression or death. Locoregional progression was defined as progression occurring in the original location or regional lymph nodes, while other progression was considered as distant progression.

Statistical methods
-------------------

Survival was assessed by the Kaplan-Meier method and compared using a log-rank test. Comparisons of categorical variables between groups were performed by Fisher\'s exact test. P-value\<0.05 (two-sided) was considered statistically significant. All tests were conducted using SPSS 21.0.

Results
=======

The incidence of MPC in patients diagnosed with ESCC and who received CRT in our hospital was 4.4% (53/1193). All malignant lesions, including NPC and MPCs, were pathological confirmed as squamous cell cancer. Out of 53 patients, 45 (84.9%) in MPC group were diagnosed with double cancers simultaneously. Others received their diagnoses between 3-21 days; with no therapy prior to complete assessments of multiple primary cancers. Clinico-pathologic characteristics are presented in **Table [1](#T1){ref-type="table"}**. Of all 53 MPC cases, 90.6% were male. Tobacco and alcohol consumption were documented 66.0% and 49.1% among this population. A family history of malignancy was identified in 26.4%. 10 (18.9%) patients were identified as underweight according to body mass index (BMI). MPCs were mainly found in esophagus (43, 81.8%), with less in the hypopharynx (8, 15.1%) and stomach (2, 3.8%). The median radiation dose delivered for primary esophageal cancer and MPC was 60 Gy (range: 50-67 Gy for primary esophageal cancer and 46-67 Gy for MPC). Concomitantly, 47 (88.7%) patients received TP or PF, and 6 (11.3%) received a single-agent regimen (platinum or 5-FU). Neoadjuvant chemotherapy was adopted in 20 (37.7%) patients, with two as the median number of cycles. Baseline clinic-pathologic characteristics were statistically balanced between MPC and NPC groups.

Toxicities
----------

In MPC group, grade 3-4 acute toxicities were reported in 34 (64.2%) patients and predominately consist of esophagitis (26 patients, 49.1%) and myelosuppression (18 patients, 34.0%), followed by 6 (11.3%) cases of severe mucositis, 4 (6.1%) cases of severe pneumonia, and other grade 3-4 adverse effects (**Table [2](#T2){ref-type="table"}**). Fifty (94.3%) patients completed the intended radiotherapy, while treatment was discontinued in 2 patients due to esophagitis, 1owe to aspiration pneumonitis. For NPC patients, grade 3-4 acute toxicities were observed in 29 (54.7%) patients (*p*=0.43). The incidence of severe esophagitis (15 patients, 28.3%,*p*\<0.001) and mucositis (0 patients, *p*=0.027) was significantly lower, while similar for myelosuppression (21 patients, 39.6%, *p*=0.69), and pneumonia (1 patients, 1.9%, *p*=0.36). The treatment completion rate was 96.2%, with 2 patients stopped radiation prematurely because of grade 3pneumonia and grade 4 laryngitis.

No severe late toxicities were recorded.

Clinical outcomes
-----------------

The response rate at 2 months after completion of CRT in MPC and NPC patients were 73.6% (39) *vs* 75.5% (40), with 11.3% (6) *vs* 24.5% (13) complete responses and 62.3% (33) *vs* 51.0% (27) partial responses. Stable disease and progressive disease was found in 18.9% (10) *vs* 20.8% (11) and 7.5% (4) *vs* 3.8% (2), respectively. The response between two groups was not statistical significant (*p*=0.28).

In MPC patients, at the median follow-up of 16 (range: 2-115) months, 36 (67.9%) patients experienced disease progression, 12 (22.6%) locoregional, 15 (28.3%) distant, 4 (7.5%) both, and 5 (9.4%) unknown. One patient with regional recurrence underwent neck dissection followed by irradiation. One patient received stereotactic body radiotherapy for solitary lung metastasis. Eight patients were prescribed chemotherapy, and the others were given best supportive treatment. At the last evaluation, there were 30 (56.6%) deaths, all but one due to disease progression.

For NPC patients, at the median follow-up of 24 (range: 4-125) months, 29 (54.7%) experienced disease progression, 6 (11.3%) locoregional, 15 (28.3%) distant, 1 (1.9%) both, and 7 (13.2%) unknown. Nine patients were given chemotherapy, and the others received best supportive treatment. At the last evaluation, 24 (45.3%) deaths were recorded, all owe to disease progression.

As calculated, the two-year overall survival (OS), progression-free survival (PFS), locoregional progression-free survival (LRPFS) and distant progression-free survival (DPFS) were 52.2% *vs* 68.9% (*p*=0.026), 32.9% *vs*54.0% (*p*=0.032), 60.8% *vs* 87.8% (*p*=0.002), 64.0% *vs* 70.8% (*p*=0.22), respectively (**Fig. [1](#F1){ref-type="fig"}**).

Based on univariate analyses (**Supplementary Table [1](#SM1){ref-type="supplementary-material"})**, male patients tended to have unfavorable PFS than female patients (2-year PFS: 36.4% *vs* 68.8%, *p*=0.026).

Discussions
===========

Consistent with the range, 4.1-10.5%, as reported previously [@B2]-[@B4], [@B6], the incidence of synchronous MPC in the upper digestive tract in patients initially diagnosed with ESCC and who underwent radiation in our hospital was 4.4% (66/1485). According to current knowledge, tobacco and alcohol abuse were the most cited features for SPM following head-and-neck squamous cell cancer [@B7]. There was also evident that lower BMI and HPV infection [@B14] were suspected risk factors. In our study, because of the way of matching, the distribution of smoking, drinking and BMI was not significantly different between groups, but noticed as a tendency. SPMs were located mainly within esophagus, followed by hypopharynx, which was also in good accordance with previous reports [@B15].

In addition to environmental or life-style associated factors, family history of malignancy was traced in 26.4% in the current study, suggesting a potential role of gene mutations and polymorphisms in the development of MPC [@B16]-[@B18]. Various types of gene alteration, i.e. loss of heterozygosity of p53, p16 and IRF, and genetic polymorphisms of aldehyde dehydrogenase type 2 (ALDH2), were already discussed, though none of specific genetic pathways were accredited to be responsible for such "field cancerization phenomenon" [@B19]-[@B20]. Recently, the relation between low ζ-chain expression in T-cells and MPC addressed the role of suppressed immune function in initialing multiple cancers, also featuring the effect of internal environment on MPC generation [@B21].

Previous studies comparing the prognosis of MPC and NPC have yielded conflicting results [@B1], [@B22]. Most of researches included heterogeneous populations, with either unbalanced clinic-pathologic characteristics, or various therapeutic strategies. Our study, matching patients by stage, age and sex, has made direct comparison of MPC and NPC of esophageal cancer. As a result of concurrent CRT, the early response rate was similar, but significantly impaired OS, PFS as well as LRPFS (2-year OS: 52.2% *vs* 68.9%, *p*=0.026; 2-year PFS: 32.9% *vs* 54.0%, *p*=0.032; 2-year LRPFS: 60.8% *vs* 87.8%, *p*=0.002) in MPC group was identified. In other words, though comparable early response rate had implied similar radiosensibility, MPC was more likely to progress, reappear or generate within 2 years. In a parallel study, 34 patients with localized synchronous head-and-neck squamous cell carcinoma and esophageal cancer were treated with concurrent CRT. Median radiation doses for head-and-neck cancer and esophageal cancer were 70 (60-70.5) Gy and 60 (45-70) Gy. As a consequence, 2-year overall survival and disease-free survival were 44% and 33% [@B11], comparable to those of the current study. Another study from Nguyen et al. reported that although 66% of cases achieved clinical complete remission at the end of neoadjuvant chemotherapy followed by radiotherapy, more than half of patients had local relapse and died from their tumor. The median survival was 12 months, with 2-year OS of only 5% [@B12]. In contrast, Welz et al. revealed a favorable median OS reaching to 37 months, but the stage of esophageal cancer tended to be earlier than that of our study [@B13]. What are the hypotheses for notably increased locoregional progression in MPC patients? First, specific genetic background may contribute to aggressive phenotype. Second, insufficient treatment intensity was under suspicion. Further studies are expected to focus on analyzing the detailed pattern of locoregional relapse to modify the current target volume and dose prescription. Third, it is natural that the presence of two or more potentially lethal tumors leads to an increased chance of relapse or dying from diseases. Fourth, persistent addiction to alcohol and tobacco may occur more frequently in MPC patients, facilitating the generation of a de novo tumor.

As a substitute of local therapy, there were uncertainties regarding the efficacy and adverse effects for surgery. Some authors figured out, even if the rate of radical resection of esophageal lesion was comparable, the presence of additional head and neck tumors was associated with a worse long-term prognosis [@B8]. According to Lee et al., when half of the resections were radical, 5-year survival was only 9.2% in patients receiving surgery for esophageal and head-and-neck cancer [@B9]. However, Otowa, Y. et al. addressed no differences in OS in patients with or without MPC receiving surgery in a non-randomized controlled study, but the extraordinarily high 5-year survival indicated possible strict selection of participants [@B10]. On the other hand, patients must be carefully evaluated before the decision of operation, because extremely invasive and complicated surgical technique, i.e. pharyngogastric or colonic anastomosis, microvascular anastomosis, myocutaneous flaps, or free jejunal grafts was sometimes required for R0 resection [@B22], which may induce increased risk of morbidity [@B23]. Thus, the decision of surgical resection should be made cautiously. In difficult cases, chemoradiotherapy served as an optimal alternative.

The prognostic factor of SPM and ESCC remained unresolved. In the current study, male patients tended to have worse PFS. Some authors believed that the primary esophageal cancer was the predominant determinant of survival since it was often more advanced at diagnosis, compared with synchronous cancer arising in other sites of the upper digestive tract [@B11]. These may leave some hints on the treatment optimization of MPC, supporting local therapy on esophageal as a priority. Recently, in synchronous squamous cell carcinoma in the upper areo-digestive tract, concomitantly elevated matrix metalloproteinases 3 and 9 levels turned out to be useful predictive biomarkers, even overcame TNM staging [@B24]. These findings also triggered interest on prognostic stratification on the basis of molecular variation and facilitate individualized treatment. However, the hypotheses should be considered cautiously and be tested by further large scale, strictly controlled studies.

Acute toxicities, especially those non-hematologic, appeared to be a major concern in our study. The incidence of severe acute grade 3-4 esophagitis and mucositis was significantly higher in MPC, as a result of extensive radiated mucosa, and usually followed by malnutrition and loss of weight. The frequent application (86.3%) of two-drug chemotherapy as the concurrent regimen may emerge as another reason. When single-drug regimens are administered concomitantly, severe toxicities have been reported in only 21% of patients and primarily involve myelosuppression [@B11]. Since low BMI has been identified as a significant inverse prognostic factor [@B25], how to reduce treatment toxicity became a vital question. High expectations were placed on more advanced radiation techniques, i.e., tomotherapy, proton therapy or heavy ion radiotherapy, adjusted concomitant chemotherapy, as well as positive nutritional support.

In the current study, we used matching to compare the prognosis of MPC and NPC following concurrent chemoradiotherapy. Since sex was one of the matched factors while drinking and smoking are sex-relevant, their distribution between MPC and NPC patients were artificially affected. Another deficiency to aware was the undetailed record of location of recurrence, which will be concerned in future studies, to analyze the association of target volume, dose prescription and relapse.

In conclusion, concurrent CRT for synchronous MPC in the upper digestive tract and esophageal cancer, based on the precision radiotherapy technique, has a worse prognosis compared to their NPC counterparts, but with more significant esophagitis and mucositis. The disappointing long-term locoregional control intrigues interest on the detailed pattern of recurrence in these patients. Future studies focusing the location of locoregional relapse and radiation volume & does may assist in determining the biological features of MPC and optimize treatments. Moreover, advanced radiation techniques may play a role in protecting normal tissues and reduce acute toxicities.
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###### 

Clinico-pathologic characteristics

  Characteristics                                   MPC   NPC                 
  ------------------------------------------------- ----- ------ ----- ------ --------
                                                    No.   \%     No.   \%     *p*
  **Age**                                                                     
  ≥60                                               24    45.3   27    50.9   *0.56*
  \<60                                              29    53.7   26    49.1   
  **Sex**                                                                     
  Male                                              48    90.6   42    79.2   *0.17*
  Female                                            5     9.4    11    20.8   
  **Location of primary esophageal cancer**                                   
  Cervix                                            16    30.2   7     13.2   *0.14*
  Upper 1/3 esophagus                               16    30.2   15    28.3   
  Middle 1/3 esophagus                              19    35.8   27    50.9   
  Lower 1/3 esophagus                               2     3.8    4     7.5    
  **Clinical stage of primary esophageal cancer**                             
  I-II                                              7     13.2   7     13.2   *1.0*
  III-IV                                            46    86.8   46    86.8   
  KPS                                                                         
  ≥90                                               44    83.0   43    81.1   *1.0*
  \<90                                              9     17.0   10    18.9   
  **Smoking**                                                                 
  Yes                                               35    66.0   37    69.8   *0.84*
  No                                                18    34.0   16    30.2   
  **Drinking**                                                                
  Yes                                               26    49.1   23    43.4   *0.70*
  No                                                27    50.9   30    56.6   
  **Family history**                                                          
  Yes                                               14    26.4   9     17.0   *0.35*
  No                                                39    73.6   44    83.0   
  **BMI**                                                                     
  \<18.5                                            10    18.9   8     15.1   *0.80*
  ≥18.5                                             43    81.1   45    84.9   
  **Concurrent chemotherapy**                                                 
  TP/PF                                             47    88.7   49    92.5   *0.74*
  5-FU/platinum                                     6     11.3   4     7.5    
  **Induction chemotherapy**                                                  
  Yes                                               20    37.7   12    22.6   *0.14*
  No                                                33    62.3   41    77.4   
  **RT technique**                                                            
  3D-CRT                                            11    20.8   18    34.0   *0.19*
  IMRT/VMAT                                         42    79.2   35    66.0   
  **RT dose for primary esophageal cancer**                                   
  ≥60 Gy                                            35    66.0   40    75.5   *0.39*
  \<60 Gy                                           18    34.0   13    24.5   
  **Location of second primary cancer**                                       
  Esophagus                                         43    81.1                
  Hypopharynx                                       8     15.1                
  Stomach                                           2     3.8                 
  **Clinical stage of second primary cancer**                                 
  I-II                                              34    64.2                
  III-IV                                            19    35.8                
  **RT dose for second primary cancer**                                       
  ≥60 Gy                                            33    62.3                
  \<60 Gy                                           20    37.7                

MPC: multiple primary cancers; NPC: non-multiple primary cancer; KPS: Karnofsky performance scale; BMI: body mass index; TP: taxane+ platinum; 5-FU: 5-fluorouracil; RT: radiotherapy; 3D-CRT: three-dimensional conformal radiotherapy; IMRT: intensity modulated radiotherapy; VMAT: volumetric modulated arc therapy; CRT: chemoradiotherapy.

###### 

Acute grade 3-4 toxicities.

  Toxicity                       MPC   NPC            
  ------------------------------ ----- ----- ---- --- -----------
  Esophagus                      31    3     12   3   *\<0.001*
  Neutropenia                    6     8     7    6   *1.0*
  Thrombocytopenia               7     0     6    2   *1.0*
  Anemia                         4     0     0    1   *0.36*
  Mucous membrane                5     1     0    0   *0.027*
  Lung                           4     0     1    0   *0.36*
  Larynx                         1     0     1    1   *1.0*
  Upper gastrointestinal tract   1     0     0    0   *1.0*
  Lower gastrointestinal tract   1     0     0    0   *1.0*
  Eye                            1     0     0    0   *1.0*

MPC: multiple primary cancers; NPC: non-multiple primary cancer.
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